Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Solid Tumors With KRAS G12C Mutations”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Looking for participantsNCT06244771
What this trial is testing

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Who this might be right for
Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more
Frontier Medicines Corporation 403
Testing effectiveness (Phase 2)Ended earlyNCT04165031
What this trial is testing

LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerColorectal Cancer
Eli Lilly and Company 5
Testing effectiveness (Phase 2)Looking for participantsNCT05410145
What this trial is testing

D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd 442
Early research (Phase 1)Study completedNCT06117371
What this trial is testing

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Who this might be right for
Advanced or Metastatic Solid TumorKRAS G12C Mutation
BeBetter Med Inc 11
Early research (Phase 1)UnknownNCT05768321
What this trial is testing

Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Who this might be right for
Advanced Solid Tumors
GenEros Biopharma Hangzhou Ltd 70
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)Active Not RecruitingNCT04699188
What this trial is testing

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Who this might be right for
KRAS G12C Mutant Solid TumorsCarcinoma, Non-Small-Cell LungCarcinoma, Colorectal+7 more
Novartis Pharmaceuticals 344
Not applicableApproved For MarketingNCT05162443
What this trial is testing

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Who this might be right for
Advanced CancerMetastatic CancerMalignant Neoplasm
Bristol-Myers Squibb
Early research (Phase 1)Study completedNCT05178888
What this trial is testing

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Who this might be right for
Advanced Solid Tumor
Mirati Therapeutics Inc. 11
Early research (Phase 1)UnknownNCT05010694
What this trial is testing

GH35 Tablets for Advanced Solid Tumors: A Study on Safety and Early Results

Who this might be right for
Advanced Solid Tumors Harboring With G12C Mutation
Suzhou Genhouse Bio Co., Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT03600883
What this trial is testing

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Who this might be right for
KRAS p.G12C Mutant Advanced Solid Tumors
Amgen 713
Testing effectiveness (Phase 2)Looking for participantsNCT05288205
What this trial is testing

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Who this might be right for
KRAS P.G12CNon-small Cell Lung CancerColorectal Cancer+1 more
Allist Pharmaceuticals, Inc. 240
Testing effectiveness (Phase 2)UnknownNCT05119933
What this trial is testing

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Who this might be right for
Advanced Solid Tumor
Shanghai YingLi Pharmaceutical Co. Ltd. 55
Early research (Phase 1)Study completedNCT04006301
What this trial is testing

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Who this might be right for
NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more
Janssen Research & Development, LLC 10
Early research (Phase 1)Active Not RecruitingNCT04973163
What this trial is testing

Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 30
Early research (Phase 1)Looking for participantsNCT06659341
What this trial is testing

A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

Who this might be right for
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer 104
Testing effectiveness (Phase 2)UnknownNCT05993455
What this trial is testing

Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab

Who this might be right for
Efficacy
Korea University Anam Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT06008288
What this trial is testing

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Who this might be right for
KRAS P.G12CPancreatic CancerSolid Tumor
Allist Pharmaceuticals, Inc. 88
Early research (Phase 1)Study completedNCT04380753
What this trial is testing

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Who this might be right for
Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation
Amgen 12
Next Page